Biotechnology Value Fund — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
BiotechBoulder, US
Nicholas Traggis(Executive Officer, Director)
BoardKyle Lefkoff(Director)inDavid Snitman(Director)William S. Marshall(Director)John Orwin(Director)
Co-investorsBoulder Ventures
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundCatalio Capital Management+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.